RxDoctor Payments Data

Angela Reed

Nurse Practitioner · Kennebunk, MENPI 1154758589

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,046 of the $1,246 with a category attached, or 84.0%. It is spread thinly across 13 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,246in general payments, 2019–2025

Across 28 payments — averaging $44.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$235
  • Daiichi Sankyo Inc.$215
  • Exelixis Inc.$206
  • Incyte Corporation$125
  • Pharmacyclics LLC, An Abbvie Company$104
  • Seagen Inc.$100
  • plus $260 from 7 others

What the payments were for

  • Food & beverage$1,04684%
  • Education$20016%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,246 in reported general payments places this provider in the 95th percentile of 740 nurse practitioner providers in Maine.

See all nurse practitioner providers in Maine

Medicare billing

Part B allowed, 2024
$299,299
Medicare patients
137
Services billed
14,524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban17$14,386
Potassium Chloride91$6,018
Ondansetron OdtOndansetron62$979
Famotidine27$860
Dexamethasone30$596
Prochlorperazine Maleate50$552
Olanzapine20$426
Methylphenidate Hcl19$417
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen20$348
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine23$345
Prednisone68$312
Morphine Sulfate ErMorphine Sulfate15$257
Levothyroxine Sodium17$156
Oxycodone Hcl14$149
Triamcinolone Acetonide14$147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$14,38617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 740 nurse practitioner providers in Maine.

Other nurse practitioner in Kennebunk

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →